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Phosphorothioate BCR-ABL Antisense Oligonucleotides Induce Cell Death, but Fail to 
Reduce Cellular Bcr-Abl Protein Levels
Toon F.CM, Smetsers, Louis T.F. van de Locht, Arie H.M. Pennings, Hans M .C Wessels, Theo M. de Witte,
and Ewald J.B.M. Mensink
Division of Hematology, University Hospital St. Radboud, Nijmegen, The Netherlands
The bcr-abl oncogene is a fusion gene resulting from a recipro­
cal translocation which forms the hallmark of chronic myeloid 
leukemia (CML). Antisense oligonucleotides complementary to 
the two possible mRNA breakpoints were found to inhibit cell 
growth of CML patient cells and cell lines, but doubt exists 
about their specificity. In order to test the specificity, phos­
phorothioate and 3'phosphorothioate capped antisense BCR- 
ABL oligonucleotides of different length were used. Stability, 
cellular uptake of oligonucleotides and effect on cell growth 
were studied in two CML cell lines, BV173 and LAMA-84. Phos­
phorothioate antisense BCR-ABL oligonucleotides were most 
stable, showed the highest uptake and induced cell death in 
BV173 but not in LAMA-84 cells. We selected the most effective 
antisense oligonucleotide for further analysis. The BV173 and 
LAMA-84 ce)i lines do not express the normal c-abl protein, wq 
therefore used a c-aW specific monoclonal antibody for the 
detection of p210bcraW expression by flow cytometry. Dead 
cells found after treatment were gated out of analysis. Although 
BCR-ABL antisense oligonucleotides can induce apoptosis, no 
reduction of p2lObcraW levels could be detected in living cells 
after treatment with antisense oligonucleotides. We conclude 
that antisense mediated inhibition of translation of mRNA into 
p210bcr ab/ is not the mechanism responsible for the induction 
of apoptosis in cell line BV173.
Keywords: antisense; p210(bcr-abl); phosphorothioate; apoptosis; 
CML
INTRODUCTION
Chronic myeloid leukemia (CML) is a myeloproliferative dis­
order characterized by an accumulation of myeloid ceils and 
their progenitors. In over 90% of CML patients a characteristic 
Philadelphia chromosome (Ph') is found. The onset of the dis­
ease is thought to occur in the hematopoietic stem cell 
because the Ph' chromosome is present in most hematopo­
ietic celi types. The Ph' chromosome is the outcome of a 
reciprocal translocation t(9;22) between the long arms of 
chromosomes 9 and 22 (1). The chromosomal regions 
involved in this transiocation harbor the c-abl proto-oncogene 
located on chromosome 9, and the BCR gene on chromosome 
22. As a result of the transiocation a bcr-abl fusion gene is 
formed. This fusion gene encodes for a 210 kDa protein with 
enhanced tyrosine kinase activity (2-4). Only two possible 
bcr-abl mRNAs occur. Exon b2 of the bcr (breakpoint cluster 
region of the BCR gene) can be spliced to c-abl exon 2 (b2a2 
breakpoint) or exon b3 to the c-abl exon 2 (b3a2 breakpoint).
The breakpoint region on the hybrid mRNA molecules is 
thought to be a unique target for antisense oligonucleotides. 
Antisense oligonucleotides are short (15-30 nt) synthetic DNA 
molecules which are actively internalized by cells (5). It is 
thought that antisense oligonucleotides bind to their comp­
lementary mRNA and inhibit translation into protein. This is
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most likely to occur by a blockade of the ribosomal translation 
mechanism or by mRNA degradation by a cytoplasmic 
enzyme RNase H, that recognizes RNA/DNA hybrid mol­
ecules (6, 7). Antisense oligonucleotides have been found use­
ful in reducing the expression of a number of genes including 
the bcr-abl gene. Unmodified 18-mer antisense oligonucleo­
tides targeted to the bcr-abl mRNA breakpoints reduced the 
clonogenic capacity of hematopoietic progenitors from the 
bone marrow of CML patients, but much less from normal 
hematopoietic progenitor cells (8-11). These 18-mer oligonu­
cleotides inhibited the growth of several CML cell lines as well 
(12-14). Because these oligonucleotides are rapidly degraded 
by serum components, more stable 26 and 18-mer phos- 
phorothioate-modified oligonucleotides were tested in cell 
lines and normal CML cells (15-1 7). Phosphorothioate 26-mer 
oligonucleotides directed against the b2a2 breakpoint 
induced programmed cell death in the CML cell line BV173 
expressing a b2a2 type bcr-abl mRNA, however B3A2 anti­
sense oligonucleotides were also effective (17). Sense oligonu­
cleotides showed only little effect on cell growth. When tested 
on cells from CML patients, 26-mer and 18-mer antisense 
phosphorothioate oligonucleotides showed little specificity for 
the CML breakpoints (16). Because of this partial sequence 
specific effect we tested oligonucleotides with different length 
and chemical constitution. Since the rationale behind the anti­
sense approach is based upon the inhibition of translation we 
tested the effects of the most effective antisense BCR-ABL oli­
gonucleotides on p2}Qhcr~i,bl levels in the CML cell lines. To 
eliminate annoying effects on this analysis from the presence 
of dead cells, we chose to do this by flow cytometry in which 
only the living cells were analyzed. The tested cell lines 
BV1 73 and LAMA-84 do not express a normal c-abl protein. 
This enabled us to use a c-ab/ specific monoclonal antibody 
to measure the p210/;cr_rl/j/ expression by flow cytometry 




Human leukemic cell lines BV173 (CML lymphoid) (18), K562 
(CML erythroblastic) (19), LAMA-84 (CML myeloid) (20), 
TOM-1 (ALL lymphoid), were cultured in RPMI 1640 medium 
(Flow Laboratories, Irvine, UK) supplemented with 10% heat 
inactivated (56°C, 30 min) fetal calf serum (Hyclone, Logan, 
UT, USA), 2 m M  L-glutamine, 50 lU/ml penicillin and 
50 fjLg/m\ streptomycin (Celiect®; ICN Flow, Irvine, UK) in a 
humidified incubator at 37°C with 5% C 0 2 in air.
Oligodeoxynucleotldes
Oligodeoxynucleotides were synthesized on an Applied Bio- 
systems DNA synthesizer model 391 EP (Applied Biosystems,
BCR-ABL Antisense and Protein Expression
Smetsers et al.
Table 1 Location, Sequence and Constitution of Oligonucleotides Used 119
Name Sequence (5' —» 3') Location Gene Exon Fragment Length
Bcr-abl and c-abl mRNA detection
Sense oligonucleotides
Al!-e1 CGCATGTTCCGGGACAAAAGC 1677-1697 ber e1 294
BA5 CGGGAGCAGCAGAAGAAGTGT 3180-3200 ber b2 • 219/294
ABL-1a AGCTGGTGGGCTGCAAATC 167-185 abl 1a 155
ABL-1b GCTTGCCTGCCCTGCAI I I 47-65 abl 1b 1b 185
Antisense oligonucleotide
BA3 GGGTCCAGCGAGAAGGI I I I 302-321 abl 2
Internal probe
«A22 GGCTT CACT CAGAGCCIGAGGCT C 259-282 abl 2
Beta-2~ microglobulin mRNA detection
B2M5 CTCGCGCTACTCTCTCI I ICT 910-930 b2m1 1 138
B2M3 T GTCGG ATT GAT G AAACCCAG 198-218 b2m2/3 2
Antisense Oligonucleotides
«B2A2.16M AAGGGCTTCTTCCTTA I 3296-3303 ber b2
B2A2.16M TAAGGAAGAAGCCCTT I 227-234 abl 2
«B3A2.16M AAGGGCI 111 GAACTC [ 3371-3378 ber b3
B3A2.16M GAGTTCAAAAGCCCTT 227-234 abl 2
aB2A2.18M GAAGGGCTTCTTCCTTAT \ 3295-3303 ber b2
B2A2.18M ATAAGGAAGAAGCCCTTC I 227-235 abl 2
aB3A2,18M GAAGGpC I II IGAACTCT 1 3370-3378 ber b3
B3A2.18M AGAGTTCAAAAGCCCTTC [ 227-235 abl 2
ÛB2A2.26M CGCTGAAGGGCTTCTTCCTTATTGAT 1 3291-3303 ber b2
B2A2.26M ATC A ATÄAGGAAGAAGCCCTTC AG CG \ 227-239 abl 2
aB3A2.26M CGCTG^AGGGC I I I IGAACTCTGCTT 3366-3378 ber b3
B3A2.26M AAGCAGAGTTCAAAAGCCCTTCAGCG 227-239 abl
■
2
PosiLions correspond to: abl, human c-abl mRNA genbank accession no. X I6416; ber, human BCR mRNA genbank accession no. Y00661; abl 
1b, human c-abl mRNA with exon 1b genbank accession no. M l 7310; b2ml, human beta-2-microglobulîn gene exon 1 genbank accession 
no. Ml 7986; b2m2/3, human beta-2 microglobulin gene exon 2 and 3 genbank accession no. M l 7987.
Foster City, CA, USA) according to the manufacturer's instruc­
tions. After deprotection in 25% ammonium hydroxide 
solution (Applied Blosystems) 8 h at 55°C, oligonucleotides 
were purified by two ethanol precipitations and dissolved in 
distilled water. Sequences of the oligonucleotides used are 
summarized in Table 1, their location is shown in Figure 1. 
Phosphorothioate (all-PS) and 3'phosphorothioate capped 
(cap-PS) oligonucleotides were synthesized using tetraethyl 
thiuram disulfide (TETD; Applied Biosystems) as a sulphuriz-
ation agent during synthesis, After deprotection and ethanol 
precipitation the oligonucleotides were purified by HPLC and 
desalted as described (17). For fluorescein labeling a 6-ami- 
nohexanol phosphate linker was attached to the oligonucleot­
ides by the use of Aminoiinl<-2 (Applied Biosystems) in normal 
synthesis. After HPLC purification, these oligonucleotides 
were coupled with (5)6-carboxyfluorescein-N-hydroxysuccin- 
imide ester (FLUOS) (Boehringer Mannheim, Mannheim, 

































Figure 1 Schematic representation of the c-abl and bcr-abl mRNAs and the location of PCR and antisense oligonucleotides used. RNA was 
reverse transcribed with hexanucleotides. PCR analysis was used to detect the c-abl and bcr-abl mRNA with oligonucleotide BA3 as antisense 
primer. Oligonucleotide aA22 was used as a probe for detection of the mRNAs
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Figure 5 (a) Cellular accumulation of FLUOS-labeled all-PS oligonucleotides in cell line BV173. (b) The same as in (a) for LAMA-84, (c) 
Cellular accumulation of FLUOS-labeled Cap-PS oligonucleotides compared to the a:B2A2.26M all-PS oligonucleotide in cell line BV173. (d) The 
same as in (c) for LAMA-84. All-PS oligonucleotides: Y, «B2A2.26M; V, B2A2.26M; •, «B2A2.16M; O , B2A2.16M. Cap-PS oligonucleotides: ♦, 
«B2A2.18M; <>, B2A2.18M; A, «B2A2.16M; A, B2A2.16M
ence of 19 U/ml Taq DNA polymerase (Gibco BRL). Samples 
were overlaid with 60 ¡jl\ of mineral oil (Sigma) and amplified 
in a DNA thermal cycler model (Perkin Elmer Cetus, Norwalk,
4
CT, USA). Samples were denatured for 5 min at 95°C. Ampli­
fication was 30 s at 94°C/ 30 s at 58°C, and 90 s at 72°C for 
30 cycles. Amplification was followed by a final extension for 
10 min at 72°C.
Electrophoresis and Blotting o f PCR Products
After amplification PCR products were separated on a 2% aga­
rose gel. The separated PCR products were transferred to a 
Hybond™~N+ nylon membrane (Amersham, Buckingham­
shire, UK). The oligonucleotide ctA22 was 5' end-labeled with
[y-32P]dATP using T4 kinase (Boehringer Mannheim). Unin­
corporated radioactivity was removed using a sephadex G-50 
spin column. Membranes were screened using the radioactive 
labeled oligomer probe according to the instructions of the 
manufacturer. After this membranes were exposed to an X- 
ray film.
Analysis o f Cellular Bcr-AbI Protein levels by Flow 
Cytometry
For analysis of Bcr-AbI protein levels, cells were washed twice 
with PBS. After this cells were incubated with 100 ¡i\ of FACS® 
lysing solution (Becton Dickinson, San José, CA, USA) for fix­
ation and permeabilization for 1 h at room temperature. Alter-
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Figure 6 Cell number of cell line BV173 after 6 days of incubation 
with different BCR-ABL antisense oligonucleotides and controls 
determined by flow cytometry
natively cells were fixed with 0.5% paraformaldehyde for 5 
min at 4°C followed by permeabilization using 0.1% Triton- 
X-100 also at 4°C for 5 min. Cells were washed once with 
PBS and placed in 96-well point bottom wells (Costar) and 
blocked for non-specific binding with 50 fi\ of PBS containing 
20% pooled human serum for 15 min at 37°C. Hybridoma 
supernatant (50 /¿I) and the polyclonal anti Ki-67 antibody 
were added and Incubated for 30 min at 4°C. Cells were 
washed three times with cold PBS containing 0.5% bovine 
serum albumin (BSA) (Organon Teknika, Boxtel, The 
Netherlands). After this, cells were incubated with PBS 20% 
human serum for 30 min at 4°C and incubated with the 
diluted FITC or RPE conjugates for 30 min at 4°C. Cells were 
washed twice with cold PBS 0.5% BSA and incubated with 
20 /LLg/ml propidium iodine (PI) in PBS for DNA staining at 
4°C. Cells were then analyzed by flow cytometry.
For flow cytometric detection of the Bcr-Abl protein, Ki-67 
antigen and DNA, a 488 nm 40 mW argon ion laser running 
at 15 tnW was used. Dichroic mirrors of 550 nm and 625 nm 
and band pass filters of 525/40 nm for green fluorescence and 
575/30 nm for red fluorescence and a 610 nm long pass filter 
for PI fluorescence were used.
RESULTS
Detection o f the c-abl and bcr-abl mRNAs in Cell 
Lines
We tested the mRNA expression of the c-abl and bcr-abf 
mRNAs in four cell lines by reverse transcriptase PCR (Figure
1). The amount and quality of RNA was checked by a PCR 
for the beta-2-microglobulin and was approximately the same 
in the four cell lines (data not shown). Only cell line TOM-1 
was positive in a PCR for detection of the e1 a2 bcr-abl mRNA 
(Figure 2). Cell lines K562 and LAMA-84 expressed the b3a2 
mRNA and BV173 the b2a2 type mRNA. Cell lines K562 and 
TOM-1 were both positive in a PCR for the detection of the 
normal c-abl mRNAs. The c-abl mRNA has two splicing vari­
ants (1 a and 1 b) that are detected with two different PCR reac­
tions. Both types of c-abl mRNA were found in these cell lines. 
Cell lines LAMA-84 and BV173 showed no product after 
reverse transcriptase PCR for the normal c-abl mRNAs. We 
therefore decided to use these cell lines for protein analysis 
using flow cytometry using a c-abl specific monoclonal anti­
body.
Stability o f Oligonucleotides in the Culture Medium
We tested the stability of 5' labeled oligonucleotides at a con­
centration of 10 juM in RPMI containing 10% FCS« The auto­
radiogram (Figure 3) shows that the unmodified phosphodies- 
ter oligonucleotide aB2A2.18M is rapidly degraded in th  ^
culture medium. An oligonucleotide with the same sequence 
containing two 3' phosphorothioate linkages (cap-PS) showed 
an enhanced stability in the culture medium and after 5 days 
full length product could still be detected. Although this oli­
gonucleotide is more stable, it is not as stable as the full phos­
phorothioate modified (all-PS) oligonucleotide «B2A2.26M, 
that only shows a slight breakdown. The same accounts for 
the 16-mer cap-PS oligonucleotides (Figure 3b). Minor phos­
phatase or 5' exonuclease activity is present in the culture 
medium since radioactivity seems to disappear from the 
aB2A2.26M band but no smaller oligonucleotide degradation 
products can be detected. All-PS oligonucleotides were found 
to be more stable than cap-PS oligonucleotides. After gel 
analysis, these oligonucleotides show several breakdown pro­
ducts. Remarkably, the sense cap-PS oligonucleotide 
B2A2.16M lacks two of these breakdown products (Figure 3b, 
marked by arrows) that are present in the antisense oligonu­
cleotide aB2A2.16M. The absent bands on the autoradiogram 
indicate that the B2A2.16M oligonucleotide is in some way 
protected from degradation, possibly by the formation of a 
secondary structure or by protein binding. The presence of 
secondary structure was confirmed by computer analysis (data 
not shown).
Cellular Levels o f FLUOS Labeled BCR-ABL 
Oligonucleotides
In order to study the cellular accumulation of BCR-ABL oli­
gonucleotides of different constitution and length in cell lines, 
we incubated BV173 and LAMA-84 cells with 10 /jlm of 
FLUOS-labeled sense and antisense B2A2 oligonucleotides. 
Because it is difficult to strip the oligonucleotide from the 
cellular membrane (5), we determined the total of cell-associ­
ated oligonucleotide. At different time periods cellular fluor­
escence was measured by flow cytometry as described before 
(17). Confocal laserscanning microscopy showed that cellular 
fluorescence was indeed present inside the cells and not only 
at the cell membrane. The all-PS 26 mer oligonucleotides 
showed a vesicular fluorescence (Figure 4a and b), the cap-PS 
oligonucleotides showed a more diffuse cellular fluorescence 
(Figure 4c and d) with less vesicles present. Figure 5a shows
the oligonucleotide uptake of sense and antisense all-PS oli­
gonucleotides of 26-mer and 16-mer length in cell line 
BV173. While the uptake of antisense oligonucleotide 
aB2A2.16M reaches a maximum after 24 h of incubation, this 
is not the case for the 26-mer oligonucleotides. LAMA-84 cells 
(Figure 5b) accumulate more oligonucleotide than BV1 73 
possibly due to differences in cell size. Unlike BV173 cells 
the 26-mer oligonucleotides are internalized better than the 
16-mer oligonucleotides and the 26-mer sense B2A2.26M bet­
ter than the antisense «B2A2.26M. Remarkably the cellular 
amount of the sense B2A2.16M showed no time dependency 
in both cell lines.
When the cellular amount of 16-mer and 18-mer cap-PS 
oligonucleotides was compared with that of the all-PS oligo­
nucleotides, they were found to internalize less effectively in 
BV173 and in LAMA-84 cells (Figure 5c and d). The 18-mer 
capped oligonucleotides accumulate more efficiently than the 
16-mer cap-PS. A very poor uptake of the sense 1 6-mer cap- 
PS and all-PS oligonucleotide was observed. Because of this 
we investigated the cellular amount of the all-PS 1 6-mer anti­
sense oligonucleotides targeted against the B2A2 as well as 
the B3A2 breakpoint after 18 h of incubation with 10 jiiM of 
oligonucleotides (data not shown). No difference in the cellu­
lar amount of the aB2A2.16M compared to aB3A2.16M in 
the cell line BV1 73 and LAMA-84 was observed. This indi­
cates that the sense 16-mer B2A2.16M clearly shows different 
uptake kinetics compared to other oligonucleotides of the 
same length.
In general, uptake of PS-oligonucJeotides is better than PS- 
capped oligonucleotides of the same length. Cellular uptake 
is length dependent. Sense 16-mers show a considerably 
reduced and no time dependent uptake.
Effect o f BCR-ABL Antisense Oligonucleotides on Cell 
Growth of B V I73 Cells and LAMA-84 Cells
Figure 6 shows cell numbers of BV1 73 after 6 days of treat­
ment with antisense BCR-ABL and control oligos. No effect 
on cell growth of LAMA-84 cells after treatment with any 
of the oligonucleotides was observed (data not shown). Cell 
growth of BV173 was dramatically reduced after addition 
of the all-PS aB2A2.26M. As discussed before, the antisense 
oligonucleotide targeted against the B3A2 breakpoint 
aB3A2.26M also inhibited cel! growth in these ceils (17). 
The control 26-mer all-PS sense oligonucleotides had little 
effect on cell growth of BV173. The 16-mer all-PS 
aB2A2.16M showed growth inhibition, while the antisense 
oligonucleotide targeted against the B3A2 breakpoint did 
not. Incubation with both 16-mer sense control oligonucle­
otides showed a drastic growth inhibition. Of the cap-PS 
oligonucleotides the aB2A2.18M showed poor inhibition of 
cell growth BV173 while all other control oligonucleotides 
of the same length had no effect. Cap-PS 16-mer oligonu­
cleotides did not induce a ceil growth reduction of cell 
line BV173.
We conclude that some of the all-PS oligonucleotides tested 
are effective in reducing cell growth of BV173 whereas cap- 
PS are not. The effectiveness depends on the sequence and 
length of the oligonucleotide. Sense 16-mer oligonucleotides 
also reduce growth of BV173. The all-PS «B2A2.26M is the 
most effective antisense oligo.
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Bcr-Abl Protein Levels after Antisense Treatment
In order to determine whether the cytotoxic effect of BCR-ABL 
antisense oligos was caused by a decrease in Bcr-Abl protein 
expression we determined p21 obcr~clbl expression using flow 
cytometry. The effect of antisense on the levels of p21 QtiCr~ijhl 
was also analyzed in LAMA-84 cells. Because the antisense 
26-mer all-PS oligonucleotides were most effective, whereas 
the 26-mer sense controls were not, we selected these oligon­
ucleotides for protein studies. Measurements of expression of 
p21 obcr-*bl after antisense treatment were complicated in 
BV173 because of induction of apoptosis (1 7). Apoptotic cells 
could be found after 4 days of incubation with antisense oli­
gonucleotides and were identified by their low DNA staining 
ability. W e analyzed cells stained for the p2'\Qbcr~abf protein in 
combination with the DNA stain propidium iodine (PI). Figure 
7 shows a dual parameter flow cytometric analysis for 
p2 i Qbcr-abi ancj ojnja of BV1 73 cells after 5 days of treatment 
with 26-mer all-PS BCR-ABL oligonucleotides. The p210bcr‘<lW 
accumulates gradually as cells pass through S phase and 
is highest in the G2/M phase of the ceil cycle. Cells with low 
PI staining, i.e. the apoptotic cells also show a low staining 
for the p21 Qhcr-ah/, Because these cells are not viable, the 
determination of Bcr-Abl protein levels in these cells is not 
reliable.
After treatment with all 26-mer ail-PS oligonucleotides, no 
decrease of p210bcr*<aW levels could be found in the cells with 
normal PI staining. Also no difference in expression during 
different phases of the cell cycle could be found. To exclude 
staining artefacts caused by improper fixation we used a con­
trol antibody specific for the Ki~67 antigen. Cells that were 
not properly fixed showed a very low staining for the Ki-67 
antigen, while dead cells showed an extremely high fluor­
escence signal after staining (data not shown). Only cells with 
a normal signal for the Ki-67 antigen were analyzed. The 
experiment was repeated at least three times at different time 
periods after incubation. A decrease in levels of cellular 
p210bcr_,lW was never observed.
Because TPA was known to decrease Bcr-Abl protein 
expression in K562 cells (24), we analyzed BV173 cells and 
LAMA-84 cells after 3 days of treatment with TPA as a positive 
control for p210fcc/w,w decrease. TPA induced cell death in 
both cell lines. Figure 8a shows flow cytometric analysis of 
p210/Jcr~a6/expression of BV173 cells with normal Ki-67 stain­
ing after 5 days of incubation with oligonucleotides and after 
3 days of treatment with TPA. Treatment of TPA resulted in a 
decrease of p210bcr-<lbl levels in these cells. The same effect of 
TPA was observed in LAMA-84 (Figure 8b).
DISCUSSION
Antisense BCR-ABL oligonucleotides have been shown to 
reduce the colony formation and cell growth of CML ceil 
lines. The observation that 26-mer and 18-mer phos- 
phorothioates complementary to both types of bcr-abl break­
point inhibit ceil growth of cells from CML patients and CML 
cell line BV173 independent of breakpoint type (16,1 7), raised 
questions about the sequence specificity of these oligonucleo­
tides. To address this issue we used phosphorothioate oligonu­
cleotides and 3' phosphorothioate capped oligonucleotides of 
different length and tested their ability to inhibit translation 
of the p210bcr'obl. Corresponding sense oligonucleotides were 
used as controls. Cell lines BV1 73 and LAMA 84 used in this 




















Figure 7 Dual parameter flow cytometric analysis of Bcr-AbI protein expression vs. DNA content in BV173 cells after 5 days of incubation 
with 26-mer phosphorothioate oligonucleotides, Arrow marks apoptotic cells
normal c-abl protein enabled us to use a c-abl specific mono­
clonal antibody for detection of p21 obcr^ bl expression by flow 
cytometry. Therefore, these cell lines provided an excellent 
model for studies on the p2'\0bcr'3bl expression.
Stability, cellular accumulation and localization and effect 
on cel! growth of all-PS and cap-PS BCR-ABL antisense and 
sense oligonucleotides complementary to both bcr-abl mRNA 
breakpoints were tested. Phosphorothioate 26 and 16-mer 
antisense oligonucleotides were most stable, accumulated 
better in the cells than phosphorothioate capped oligonucleo­
tides and inhibited the growth of BV1 73 but not of LAMA-84. 
The 26-mer PS antisense oligonucleotides showed no speci­
ficity for either breakpoint while 16-mer antisense oligonucle­
otides did. Unlike the sense 26-mer PS oligonucleotides/ both 
sense 16-mer PS oliognucleotides showed strong growth inhi­
bition of cell line BV173 as well. Their degradation pattern is 
different and their cellular accumulation is low and shows no 
time dependency compared to the corresponding antisense 
oligonucleotides. It is therefore not likely that a sequence 
specific cellular mechanism is engaged in cell death induced 
by these oligonucleotides.
The 26-mer phosphorothioate antisense oligonucleotides 
were the most cytotoxic. Corresponding control oligonucleo­
tides showed no growth inhibition, W e selected these oligo­
nucleotides for determination of their effect on p21ohcr‘abl lev­
els and to test the rationale of antisense inhibition of 
translation. To discriminate between the Bcr-AbI protein levels 
in dead and living cells, we used a flow cytometric detection. 
Staining of DNA with PI and the usage of the Ki-67 mono­
clonal antibody allowed us to gate out apoptotic cells. We 
observed that in all-PS antisense 26-mer treated cells the lev­
els of the Bcr-AbI protein did not decrease in the remaining 
non-apoptoiic cells. As expected (24), we could detect a 
decrease of p2\0hcr'i,bl levels in LAMA-84 and BV173 cells 3 
days after treatment with TPA. These data show that a 
decrease in p2'\Qbcr'abl levels indeed can be detected by the 
flow cytometric method used. A decrease of p21 obc™b( levels 
is not necessarily linked to immediate cell death. In cell line 
BA/F3bcr'clW cell death could already be detected after 12 h of 
treatment with unmodified BCR-ABL antisense oligonucleot­
ides (12). Considering the half-life of the p210bCMh/, which is 
over 24 h (25), and the kinetics of oligonucleotide accumu­
lation it is also not likely that a decrease of p210/,cr'*lW in this 
cell line was responsible for the effect.
One could think of several explanations for the inhibition 
of cell growth found after antisense BCR-ABL oligonucleotide 
incubation without the expected decrease in levels of 
P 2 1  ohc:™blt
First, a slight decrease in p2'\0bcr'abl levels could induce 
immediate cell death, thereby not allowing detection of cells 
with low p210/,cr_tlW. This explanation is not likely, because 
TPA reduced p210bcr'aW levels in BV173 and LAMA-84 cells, 
that did not (yet) die of apoptosis. Also LAMA-84-cells, that 
do not die after BCR-ABL antisense treatment, do not show a 
protein decrease, indicating that at least in this cell line it is 
clear that no protein decrease exists after antisense BCR-ABL 
treatment. Furthermore, because the half-life of the p21 Qbcr-abf 
is very long it is also not likely that, if even a minor protein 
decrease exists, it could not be detected.
A second explanation for the observed growth inhibition of 
BV173 cells is a non-sequence specific toxic effect induced 
by the phosphorothioate oligonucleotides, Non-sequence 
specific effects mediated by binding of growth factors, induc­
tion of transcription factors or by oligonucleotide degradation 
products have been described (26-28). Possibly, the all-PS 16- 
mer sense oligonucleotides used in this study induce cell 
death by one of these mechanisms. We demonstrated 
sequence-dependent effects of the antisense 26-mer and 16- 
mer phosphorothioate oligonucleotides on cell growth of cell 
line BV1 73. It is however possible that only the antisense oli­
gonucleotides and not the control oligonucleotides bind a 
protein or produce toxic degradation products thereby 
inducing apoptosis. Recently it was found that oligonucleot­
ides containing the sequence GGC can bind to the p210bcr'abl 
thereby inhibiting its autophosphorylation (29). The antisense 
oligonucleotides used in this study also contain the sequence 
GGC while the sense oligonucleotides do not. This therefore 
can be an explanation for the effect The oligonucleotide 
«B3A2.16M does not reduce cell growth of BV173 while 
«B2A2.16M does. Both oligonucleotides contain the GGC 
motif. This indicates that the GGC mediated p210bcr'abl func­
tion inhibition is not the only cause of growth inhibition of 
cell line BV173. More data from carefully controlled antisense









Figure» (a) Flow cytometric analysis of Bcr-AbI protein expression in BV173 cells by staining with the 8E9 monoclonal antibody after 5 
days of treatment with 26-mer phosphorothioate oligonucleotides, and after 3 days with TPA. Cells were gated on scatter and normal Ki-67 
expression....., CD-2 MoAb negative control;---, untreated control;----- , oligonucleotide or TPA treated
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Figure 8 (b) The same as in (a) for LAMA-84 cells
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experiments are needed to determine to what extent the anti­
sense effect is mediated by protein binding.
A third and entirely hypothetical explanation for the growth 
inhibition of BV173 cells is that the presence of 
mRNA/oligonucleotide hybrids as such act as a signal for the 
onset of an apoptotic pathway. Unlike most CML cell lines, 
BV173 contains a wild type p53 gene (30), that is known to 
be involved in some mechanisms of apoptosis induction. The 
p53 protein preferentially binds to free single-stranded DNA 
ends and promotes renaturation (31). it may therefore have a 
function in antisense-mediated cytotoxicity. Cell line LAMA- 
84 contains a mutant p53 gene and could therefore be less 
sensitive. We are currently testing the involvement of p53 in 
antisense mediated cytotoxicity using transfection studies. 
Whatever the direct mechanism of action of antisense oligon­
ucleotides, the cellular background in which the experiments 
are performed is important. In our hands, BV173 is the most 
sensitive cell line for a BCR-ABL antisense approach. It could 
therefore be susceptible to induction of apoptosis by other 
mechanisms not induced by p2'\ 0bcT'jbl decrease. Although 
sequence-dependent effects of antisense BCR-ABL oligonucle­
otides are found in cell line BV173, our experiments on 
p2i obcr~abl levels indicate that these are not a result of the pro­
posed antisense mediated inhibition of translation of bcr~$&! 
mRNA.
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